Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:INSP NASDAQ:TNDM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINSPInspire Medical Systems$41.79+4.4%$52.99$39.61▼$152.36$1.15B0.831.33 million shs1.60 million shsTNDMTandem Diabetes Care$13.53+5.5%$19.87$9.98▼$29.65$878.54M1.642.53 million shs4.72 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINSPInspire Medical Systems+4.37%-3.60%-27.42%-30.87%-72.62%TNDMTandem Diabetes Care+5.54%-8.40%-34.35%-28.18%-41.38%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINSPInspire Medical Systems$41.79+4.4%$52.99$39.61▼$152.36$1.15B0.831.33 million shs1.60 million shsTNDMTandem Diabetes Care$13.53+5.5%$19.87$9.98▼$29.65$878.54M1.642.53 million shs4.72 million shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINSPInspire Medical Systems+4.37%-3.60%-27.42%-30.87%-72.62%TNDMTandem Diabetes Care+5.54%-8.40%-34.35%-28.18%-41.38%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINSPInspire Medical Systems 2.10Hold$85.00103.38% UpsideTNDMTandem Diabetes Care 2.52Moderate Buy$29.63119.01% UpsideCurrent Analyst Ratings BreakdownLatest TNDM and INSP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/18/2026TNDMTandem Diabetes Care Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$35.00 ➝ $25.005/13/2026INSPInspire Medical Systems Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell5/11/2026TNDMTandem Diabetes Care BenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageHold5/11/2026TNDMTandem Diabetes Care Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/11/2026TNDMTandem Diabetes Care BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOverweight$56.00 ➝ $55.005/11/2026TNDMTandem Diabetes Care Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$35.00 ➝ $31.005/8/2026TNDMTandem Diabetes Care MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$24.005/7/2026INSPInspire Medical Systems OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Perform5/6/2026INSPInspire Medical Systems Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D)5/5/2026INSPInspire Medical Systems Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetSector Perform$56.00 ➝ $45.005/5/2026INSPInspire Medical Systems EvercoreSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$55.00(Data available from 5/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINSPInspire Medical Systems$911.98M1.32$2.99 per share13.98$26.88 per share1.55TNDMTandem Diabetes Care$1.03B0.90N/AN/A$2.29 per share5.91Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINSPInspire Medical Systems$145.42M$4.499.3125.964.1414.33%10.35%8.81%8/3/2026 (Estimated)TNDMTandem Diabetes Care-$204.71M-$1.40N/AN/AN/A-9.20%-53.88%-7.88%8/5/2026 (Estimated)Latest TNDM and INSP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026TNDMTandem Diabetes Care-$0.46-$0.30+$0.16-$0.30$240.41 million$247.22 million5/4/2026Q1 2026INSPInspire Medical Systems-$0.2753$0.10+$0.3753-$0.39$200.04 million$204.58 million2/19/2026Q4 2025TNDMTandem Diabetes Care-$0.05-$0.01+$0.04-$0.01$277.14 million$290.38 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthINSPInspire Medical SystemsN/AN/AN/AN/AN/ATNDMTandem Diabetes CareN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINSPInspire Medical SystemsN/A6.344.48TNDMTandem Diabetes Care4.543.583.07Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINSPInspire Medical Systems94.91%TNDMTandem Diabetes CareN/AInsider OwnershipCompanyInsider OwnershipINSPInspire Medical Systems2.20%TNDMTandem Diabetes Care2.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINSPInspire Medical Systems1,33328.81 million28.18 millionOptionableTNDMTandem Diabetes Care2,50068.53 million67.09 millionOptionableTNDM and INSP HeadlinesRecent News About These CompaniesTandem Diabetes Care, Inc. (NASDAQ:TNDM) Receives Consensus Recommendation of "Moderate Buy" from AnalystsMay 16 at 3:39 AM | americanbankingnews.comCritical Analysis: Tandem Diabetes Care (NASDAQ:TNDM) & Imris (OTCMKTS:IMRSQ)May 15, 2026 | americanbankingnews.comTandem Diabetes’s Q1 earnings call: Our top 5 analyst questionsMay 14, 2026 | msn.comTNDM stock down following Q1 earnings & revenue beat, gross margin upMay 14, 2026 | msn.comTNDM Stock Down Following Q1 Earnings & Revenue Beat, Gross Margin UpMay 14, 2026 | zacks.comTandem Diabetes Care, Inc. (TNDM) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 13, 2026 | seekingalpha.comTandem Diabetes Care (TNDM) Loses 26.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerMay 12, 2026 | zacks.comTandem Diabetes Care (NASDAQ:TNDM) Given "Buy" Rating at Truist FinancialMay 12, 2026 | americanbankingnews.comTandem Diabetes Care, Inc. 2026 Q1 - Results - Earnings Call PresentationMay 11, 2026 | seekingalpha.comTandem Diabetes Care (NASDAQ:TNDM) Receives "Buy" Rating from Truist FinancialMay 11, 2026 | marketbeat.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) First-Quarter Results: Here's What Analysts Are Forecasting For This YearMay 11, 2026 | finance.yahoo.comTandem Diabetes Care, Inc. $TNDM Shares Acquired by Vanguard Group Inc.May 11, 2026 | marketbeat.comTandem Diabetes Care (TNDM) Gets a Buy from Piper SandlerMay 10, 2026 | theglobeandmail.comTandem Diabetes Care, Inc. (TNDM) Q1 2026 Earnings Call TranscriptMay 10, 2026 | seekingalpha.comTandem Diabetes Care Q1 Earnings Call HighlightsMay 9, 2026 | marketbeat.comTandem to submit tubless pump to FDA with Street-beating Q1 on record pump shipmentsMay 8, 2026 | drugdeliverybusiness.comDTandem Diabetes Care Charts Growth Amid TransitionMay 8, 2026 | tipranks.comTandem Diabetes Care (NASDAQ:TNDM) Shares Gap Up After Earnings BeatMay 8, 2026 | marketbeat.comTNDM Q1 deep dive: Margin expansion and pipeline advances amid business model shiftMay 8, 2026 | msn.comTandem Diabetes’s (NASDAQ:TNDM) Q1 CY2026: Beats On Revenue, Stock Jumps 10.9%May 8, 2026 | finance.yahoo.comBuy Rating Reaffirmed on Tandem Diabetes Care as Fundamentals Strengthen; $28 Price Target MaintainedMay 7, 2026 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTNDM and INSP Company DescriptionsInspire Medical Systems NYSE:INSP$41.79 +1.74 (+4.35%) Closing price 05/18/2026 03:59 PM EasternExtended Trading$41.97 +0.18 (+0.42%) As of 05/18/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.Tandem Diabetes Care NASDAQ:TNDM$13.53 +0.71 (+5.54%) Closing price 05/18/2026 04:00 PM EasternExtended Trading$13.49 -0.04 (-0.27%) As of 05/18/2026 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Applied Optoelectronics Stock May Be Near a Turning Point Is Everspin Technologies the Next AI Edge Breakout? 5 Robotics Stocks to Watch as Physical AI Builds Momentum Willing and Abel: Berkshire's New CEO Makes Huge Portfolio Changes in Q1 Peloton Stock Gives Back Gains After Upbeat Earnings Report 3 Infrastructure Stocks Fueling the Data Center Building Boom MarketBeat Week in Review – 05/11 - 05/15 Insider Buying Says Upstart Isn’t Down for the Count Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
